Decoy Therapeutics Inc. Asset Resilience Ratio
Decoy Therapeutics Inc. asset resilience ratio. Decoy Therapeutics Inc. (DCOY) has an Asset Resilience Ratio of 7.68% as of March 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DCOY defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Decoy Therapeutics Inc. (2015–2017)
Asset resilience ratio of Decoy Therapeutics Inc. from 2015 to 2017. This chart shows how Decoy Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Read debt load of Decoy Therapeutics Inc. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Decoy Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Decoy Therapeutics Inc. total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.00 Million | 7.68% |
| Total Liquid Assets | $2.00 Million | 7.68% |
Asset Resilience Insights
- Limited Liquidity: Decoy Therapeutics Inc. maintains only 7.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Decoy Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Decoy Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Decoy Therapeutics Inc. Asset Resilience Ratio by Year (2015–2017)
Decoy Therapeutics Inc. asset resilience ratio by year from 2015 to 2017. The table below shows the annual Asset Resilience Ratio data for Decoy Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 40.38% | $14.13 Million | $34.99 Million | -20.78pp |
| 2016-12-31 | 61.15% | $38.66 Million | $63.21 Million | +35.22pp |
| 2015-12-31 | 25.93% | $24.65 Million | $95.07 Million | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more